Device Trial Radar · NCT07684664
Allurion Gastric Balloon PAS
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Feb 19, 2029
Study completion Apr 20, 2029
Sponsor
- Lead sponsor
- Allurion TechnologiesNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS).
Conditions
- Obesity (BMI>30)
- Obesity & Overweight
Interventions
Active Elipse DeviceDevice
Intervention Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Procedure- or Device-Related Serious Adverse Events (SAEs)Time frame: Through 48 weeks (from first balloon placement on Day 0 through end of second balloon therapy period)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.